Low molecular weight heparin stimulates megakaryocytopoiesis in bone-marrow transplantation patients.
The use of low molecular weight heparin (LMWH) as prophylaxis for veno-occlusive disease of the liver has been studied in patients undergoing bone marrow transplantation (BMT). The present study analyzes the effect of LMWH on the time course of platelet recovery after BMT. Significantly accelerated platelet recovery in conjunction with lessened requirements of platelet transfusions was observed in the LMWH-treated patients.
Or
R
R
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Elad
S
S
Shpilberg
O
O
Eldor
A
A
D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use; D001682:Biological Availability; D001791:Blood Platelet Disorders / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000502:physiology*; D017984:Enoxaparin / Q000494:pharmacology* / Q000627:therapeutic use; D005240:Feasibility Studies; D006207:Half-Life; D006801:Humans; D007279:Injections, Subcutaneous; D008533:Megakaryocytes / Q000187:drug effects*; D010976:Platelet Count; D013997:Time Factors; D016896:Treatment Outcome
D000925:Anticoagulants; D017984:Enoxaparin